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inflammation prospectively over 12 months
J. Deane1,2,3, N.J. Ronan2,4, G.P. O’Callaghan2,4,5, F. Fouhy1, M.C. Rea1,5,
O. O’Sullivan1,5, C.J. Hill3,5, F. Shanahan5,6, R.P. Ross3, M. McCarthy4,
D.M. Murphy2,4, J.A. Eustace2, C. Stanton1,5, B.J. Plant2,4,5. 1Teagasc Food
Research Centre, Moorepark, Fermoy, Ireland; 2HRB Clinical Research Facility,
University College Cork, Cork, Ireland; 3School of Microbiology, University College
Cork, Cork, Ireland; 4Cork Adult Cystic Fibrosis Centre, University College Cork,
Cork University Hospital, Cork, Ireland; 5Alimentary Pharmabiotic Centre, University
College Cork, National University of Ireland, Cork, Ireland; 6Department of Medicine,
University College Cork, National University of Ireland, Cork, Ireland
Objectives: Ivacaftor is effective in the treatment of patients with CF and the G551D
gating mutation. We present faecal analysis results of the CORK cohort, a single-centre,
adult (n = 20), prospective, longitudinal study of G551D clinical responders (median
follow-up 12 months), examining the gut microbiota, exocrine pancreatic function and
intestinal inflammation on a 3 monthly basis after commencing treatment.
Methods: Stool samples pre- and 3 monthly post commencement of ivacaftor in 20
adult patients underwent metagenomic profiling of faecal microbiota. Faecal elastase-1
(FE-1), faecal calprotectin (FC) and faecal lactoferrin (FL) were measured using
commercially available ELISA kits.
Results: Ivacaftor did not significantly alter gut microbial diversity, as measured by
chao1 (p = 0.886). At phylum, family and genus levels significant increases were
observed in Bacteroidetes (p = 0.044), Bacteroidaceae (p = 0.021) and Bacteroides
(p = 0.021). Significant decreases were observed in Microbacteriaceae (p = 0.003) and
Eubacteriaceae (p = 0.014). A significant positive correlation was seen between FEV1
and gut microbiota diversity following treatment (r = 0.4, p = 0.002). No significant
difference was measured in levels of FE-1 (p = 0.267), FC (p = 0.406) or FL (p = 0.779).
Conclusion: Ivacaftor therapy has a normalisation effect on the gut microbiota,
directing the microbiota towards a non-CF profile. Despite this elevated intestinal in-
flammation was sustained. Lack of exocrine pancreatic recovery may reflect established
exocrine pancreatic dysfunction in an adult cohort. On-going longitudinal prospective
data may demonstrate further improvements in the gut health of this cohort.
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Gastro-oesophageal reflux disease (GORD) has been implicated in the respiratory
symptoms of CF. Studies in small populations suggest GORD may be present in
up to 40% of these infants.
Aim: To describe the prevalence of GORD in a large cohort of infants with CF
diagnosed by NBS. The secondary aim was to look for an association with bacterial
infection.
Methods: Our NBS surveillance programme includes a 24 hr dual probe pH study
and BAL for microbiology. Results were collected on infants over a 6 year period.
GORD was diagnosed using ESPGHAN criteria: corrected reflux index (RI) >12%,
reflux episodes >72, length of longest reflux episode >41 minutes. An association
between GORD and positive bacterial samples was explored.
Results: Infants: n = 117, median age: 4.1 months (range 1.8−9.7 mo), 57 males
(48%), 15 pancreatic insufficient (13%). 103 had valid pH studies (88%). RI >12%
n= 44 (43%), reflux episodes >72 n = 55 (53%), reflux episodes >41min n = 2.
Positive bacteria at BAL = 29%. Including: PA= 3, SA= 8, HI = 5, coliforms = 7,
other = 8 (some with mixed growths). There was no statistical difference in bacteria
between those with and without GORD. There was a significant difference in
wt z score −0.98 vs −0.2 p< 0.02. A scatter plot showed no significant reduction
in RI with age.
Discussion: This large study confirms the high prevalence of GORD in infants with
CF when using RI alone (43%), the true prevalence may be higher, 53% showed an
abnormally high number of reflux episodes. No association with bacterial infection
was found.
In conclusion: GORD appears more prevalent than thought in infants with CF and
the significantly lower weight in this group needs further exploration.
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Background: Cystic fibrosis (CF) related liver disease (CFLD) is diagnosed using
a combination of criteria. Transient elastography (TE) (ultrasonographic method
evaluating liver stiffness) differentiates CF patients with and without liver disease
(CFnoLD) and identifies patients with an increased risk for portal hypertension.
Aim: Detect evolving CFLD using TE measurements.
Method: Retrospective study (2007–2013) including all patients with TE measure-
ments, performed by the same operator. Measurement was correlated to the presence
or development of CFLD based on the medical files.
Results: 150 CF patients [median age 17 (9−24) years] were included, 118 with
repeated TE: 20 (14%) had CFLD at the first TE measurement, 4 (3%) developed
CFLD during follow-up. The median TE value in CFLD was 14 (8.7–32.2)
compared to 5.3 (4.9−5.7) in CFnoLD (P = 0.0001). The intra-individual differences
between 2 consecutive measurements [median interval between measurements
1 yr (1−2)] was 0.05 (−1, 1.2) in CFnoLD and 0.55 (−1.68, 1.53) in the CFLD
patients. The area under the receiver operating curve for TE predicting CFLD
was 0.985. TE measurements above 6.55 kPa predicted CFLD with a sensitiv-
ity of 94.7% and a specificity of 90.8% according to the AUROC. In CF <14 years a
TE measurement above 6.55 kPa had a positive predictive value of 83%, decreasing
to 60% for the total group and a negative predictive value of 100%. Patients with
developing CFLD had progressively increasing TE measurements.
Conclusion: TE measurements progressively increased in CF patients developing
CFLD. A prospective study is needed to evaluate whether TE will be able to detect
CFLD before it becomes clinically apparent.
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Objectives: Portal hypertension (PHT) is the main complication of cystic fibrosis
liver disease (CFLD) but severe liver dysfunction occurred only in 0.5% of the
patients. The early diagnosis of CFLD is elusive and a gold standard for diagnosis
of liver disease is lacking. The aim of this study was to evaluate liver stiffness
measurement (LSM) and CT with IV injected contrast medium in CF adult patients.
Median LSM in 241 CF patients was 5.9 kPa.
Methods: 57 CF patients (28F, 33 yrs −18; 51) had LSM and CT done for lung
transplant assessement or after lung transplantation.
Results: LSM was obtained in 53 patients (92%). PHT was evident on CT in 25
patients (portosystemic collaterals 12, splenomegaly 19, proeminent portal vein 25).
PHT was present in 60% of the patients when LSM was >5.9 and in 12%
when LSM was <5.9. None of the patients had variceal bleeding but 20/25 had
screening for esophagal varices and 5 preventive variceal ligation (LSM 41.6,
range 20−64). Nine patients had transient and easy to treat ascitis after lung
transplantation. Only one patient (with good respiratory function) had refractory
ascitis (LSM 64). Three patients received a combined lung and liver transplantation
(LSM: 29/39/73 kPa). Explanted liver analysis disclosed absence of cirrhosis but
obliterative portal venopathy.
Conclusion: CFLD with PHT could be present in patient with low LSM. Decom-
pensation of PHT is unfrequent even in adults with end stage pulmonary disease
or after lung transplantation. Portal venopathy without cirrhosis could explain
PHT. The mechanism remains obscure but could explain the rare occurence of
hepatocellular deficiency in CFLD.
